Clevudine

DB06683InvestigationalSmall molecule

Investigated for use/treatment in hepatitis (viral, B).

Chemical structure of Clevudine
Mechanism
Curator reviewed · 3 references
Primary indication
Investigated for use/treatment in hepatitis (viral, B).Curator reviewed · 2 structured indications
Formula / weight
C10H13FN2O5 · 260.221 g/mol (avg)

Resolves to

Compound
UNIIIN51MVP5F1CAS163252-36-6ChEMBLCHEMBL458875ChEBI135964
Clinical / RWD
ATCJ05AF12
Structure
InChIKeyGBBJCSTXCAQSSJ-XQXXSGGOSA-NSMILESCC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O
Targets
P03156P

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
14Drug interactionsStructured to mechanism, not free text
Sign in
17Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Clevudine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In